Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation

Biological Chemistry

Volumn 391, Issue 2-3, 2010, Pages 197-205

  Malcikova, Jitka ^a   Tichy, Boris ^a   Damborsky, Jiri ^b   Kabathova, Jitka ^a   Trbusek, Martin ^a   Mayer, Jiri ^a   Pospisilova, Sarka ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

R337C; Real time PCR; Reporter gene assay; Transactivation

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CARBOXY TERMINAL SEQUENCE; EXPRESSION VECTOR; GENE ACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC TRANSFECTION; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN MICROARRAY; PROTEIN VARIANT; REPORTER GENE; TP53 GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION; WILD TYPE;

BINDING SITES; CELL LINE, TUMOR; DNA; GENETIC VARIATION; HUMANS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PROTEIN ARRAY ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77749343029     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.027     Document Type: Article

References (35)

1. Atz, J., Wagner, P., and Roemer, K. (2000). Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. J. Cell. Biochem. 76, 572-584.
2. Barnes, D.M., Hanby, A.M., Gillett, C.E., Mohammed, S., Hodgson, S., Bobrow, L.G., Leigh, I.M., Purkis, T., MacGeoch, C., Spurr, N.K., et al. (1992). Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340, 259-263.
3. Blagosklonny, M.V. (2000). p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J. 14, 1901-1907.
4. Boutell, J.M., Hart, D.J., Godber, B.L., Kozlowski, R.Z., and Blackburn, J.M. (2004). Functional protein microarrays for parallel characterisation of p53 mutants. Proteomics 4, 1950-1958.
5. Braithwaite, A.W., Del Sal, G., and Lu, X. (2006). Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ. 13, 984-993.
6. Brazda, V., Muller, P., Brozkova, K., and Vojtesek, B. (2006). Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochem. Biophys. Res. Commun. 351, 499-506.
7. Chene, P. (2001). The role of tetramerization in p53 function. Oncogene 20, 2611-2617.
8. Chene, P. and Bechter, E. (1999). p53 mutants without a functional tetramerisation domain are not oncogenic. J. Mol. Biol. 286, 1269-1274.
9. Chene, P., Mittl, P., and Grutter, M. (1997). In vitro structure-function analysis of the β-strand 326-333 of human p53. J. Mol. Biol. 273, 873-881.
10. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355.
11. Clore, G.M., Omichinski, J.G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., and Gronenborn, A.M. (1994). High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265, 386-391.
12. Clore, G.M., Ernst, J., Clubb, R., Omichinski, J.G., Kennedy, W.M., Sakaguchi, K., Appella, E., and Gronenborn, A.M. (1995). Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 2, 321-333.
13. Davison, T.S., Yin, P., Nie, E., Kay, C., and Arrowsmith, C.H. (1998). Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17, 651-656.
14. el-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
15. Falke, D., Fisher, M., Ye, D., and Juliano, R.L. (2003). Design of artificial transcription factors to selectively regulate the pro- apoptotic bax gene. Nucleic Acids Res. 31, e10.
16. Friedman, P.N., Chen, X., Bargonetti, J., and Prives, C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90, 3319-3323.
17. Grochova, D., Vankova, J., Damborsky, J., Ravcukova, B., Smarda, J., Vojtesek, B., and Smardova, J. (2008). Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. Oncogene 27, 1243-1252.
18. Ishioka, C., Englert, C., Winge, P., Yan, Y.X., Engelstein, M., and Friend, S.H. (1995). Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 10, 1485-1492.
19. Kato, S., Han, S.Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., and Ishioka, C. (2003). Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 100, 8424-8429.
20. Kawaguchi, T., Kato, S., Otsuka, K., Watanabe, G., Kumabe, T., Tominaga, T., Yoshimoto, T., and Ishioka, C. (2005). The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24, 6976-6981.
21. Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
22. Laptenko, O. and Prives, C. (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13, 951-961.
23. Lomax, M.E., Barnes, D.M., Gilchrist, R., Picksley, S.M., Varley, J.M., and Camplejohn, R.S. (1997). Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene 14, 1869-1874.
24. Lomax, M.E., Barnes, D.M., Hupp, T.R., Picksley, S.M., and Camplejohn, R.S. (1998). Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene 17, 643-649.
25. Mateu, M.G. and Fersht, A.R. (1998). Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligo-merization status of tumour suppressor p53 tetramerization domain. EMBO J. 17, 2748-2758.
26. Murray-Zmijewski, F., Slee, E.A., and Lu, X. (2008). A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol. 9, 702-712.
27. Olivier, M., Petitjean, A., Marcel, V., Petre, A., Mounawar, M., Ply-moth, A., de Fromentel, C.C., and Hainaut, P. (2009). Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 16, 1-12.
28. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., and Olivier, M. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629.
29. Riley, T., Sontag, E., Chen, P., and Levine, A. (2008). Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412.
30. Rollenhagen, C. and Chene, P. (1998). Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int. J. Cancer 78, 372-376.
31. Smardova, J., Nemajerova, A., Trbusek, M., Vagunda, V., and Kovarik, J. (2001). Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol. 22, 59-66.
32. Szak, S.T., Mays, D., and Pietenpol, J.A. (2001). Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21, 3375-3386.
33. Varley, J.M., McGown, G., Thorncroft, M., Cochrane, S., Morrison, P., Woll, P., Kelsey, A.M., Mitchell, E.L., Boyle, J., Birch, J.M., et al. (1996). A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 12, 2437-2442.
34. Vousden, K.H. and Lane, D.P. (2007). p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283.
35. Waterman, J.L., Shenk, J.L., and Halazonetis, T.D. (1995). The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14, 512-519.